Events

Protected: [Webinar] How will AI solve the current orphan and oncology drugs pricing problem?

24 April 2023
Posted in ,

There is no excerpt because this is a protected post.

Read More

GPI attending ISPOR 23, Boston

13 April 2023
Posted in

GPI will be attending ISPOR, US, held at the Boston Convention Centre, Boston on the 7-10 May.

Read More

GPI to be chief sponsors of IMAS’, Access 2023

7 March 2023
Posted in

GPI are excited to be chief sponsors of Access 2023, held in Miami, Florida on 3-5 April 2023.

Read More

GPI attending the World EPA Congress

24 February 2023
Posted in

GPI will be attending World EPA Congress, held in Amsterdam on 21-23 March 2023.

Read More

[Webinar] How To Unlock Market Access and Pricing Potential of an Orphan Drug

6 November 2022
Posted in , ,

Minimising uncertainty for biopharmaceutical payers and manufacturers is a key factor in maximising pricing and market access of orphan drugs.

Read More

GPI attending the World Orphan Drug Congress

31 October 2022
Posted in

GPI will be attending World Orphan Drug Congress, held in Barcelona Spain on 14-17 November 2022.

Read More

GPI attending the EPP Life Sciences Forum

5 October 2022
Posted in

GPI will be attending the EPP Life Sciences Forum, held in Zurich, Switzerland on 18-20 October 2022.

Read More

GPI Conference Tour

29 September 2022
Posted in

GPI will be attending four in-person conferences in October & November, talking to clients and showcasing our latest initiatives, products updates and presenting research. Our conference attendance includes: Reuters: Pharma, WODC, EPP and ISPOR, where will be showcasing four research posters.

Read More

GPI to present four research posters at ISPOR

29 September 2022
Posted in

GPI will be presenting four research posters at ISPOR,held at the Austria Center, Vienna, Austria on 6-9 November 2022.

Read More

[Webinar] Cell and gene therapies in Europe: Industry’s next frontier

28 September 2022
Posted in , ,

Cell and gene therapies (CGTs) offer potential curative and restorative treatments for previously untreatable diseases. This comes at an extremely high cost with some CGTs exceeding one million Euros.

Read More